Walsh John P, Bremner Alexandra P, Bulsara Max K, O'Leary Peter, Leedman Peter J, Feddema Peter, Michelangeli Valdo
Department of Endocrinology and Diabetes, Sir Charles Gairdner Hospital, Perth, Western Australia, Australia.
Clin Endocrinol (Oxf). 2006 Oct;65(4):486-91. doi: 10.1111/j.1365-2265.2006.02619.x.
Overt hypothyroidism and hyperthyroidism are associated with hypertension, but it is uncertain whether the same is true of subclinical hypothyroidism and hyperthyroidism.
DESIGN, SUBJECTS AND MEASUREMENTS: Cross-sectional study of 2033 participants (aged 17-89 years) in the Busselton Thyroid Study who did not have a history of thyroid disease. Systolic blood pressure (SBP), diastolic blood pressure (DBP) and the prevalence of hypertension (defined as SBP >or=140 mmHg, DBP >or=90 mmHg or on treatment for hypertension) in subjects with thyroid dysfunction and euthyroid subjects were compared using linear regression models. Subjects with treated hypertension (N = 299) were excluded from analyses of SBP and DBP but included in analyses of hypertension prevalence.
Mean SBP, DBP and the prevalence of hypertension did not differ significantly between subjects with subclinical hypothyroidism (N = 105) and euthyroid subjects (N = 1859), nor did they differ between subjects with serum TSH concentrations in the upper reference range (2.0-4.0 mU/l; N = 418) and those with TSH concentrations in the lower reference range (0.4-2.0 mU/l; N = 1441). The prevalence of hypertension was higher in subjects with subclinical hyperthyroidism than euthyroid subjects (prevalence odds ratio 2.8, 95% confidence interval 1.3-6.0 adjusted for age, age(2) and sex), but this was based on a small number of subjects with subclinical hyperthyroidism (N = 35).
Subclinical hypothyroidism is not associated with hypertension. The observed association between subclinical hyperthyroidism and hypertension requires confirmation in a larger sample.
显性甲状腺功能减退和甲状腺功能亢进与高血压相关,但亚临床甲状腺功能减退和甲状腺功能亢进是否同样如此尚不确定。
设计、研究对象与测量方法:对2033名(年龄17 - 89岁)未患甲状腺疾病的巴瑟尔顿甲状腺研究参与者进行横断面研究。使用线性回归模型比较甲状腺功能异常受试者和甲状腺功能正常受试者的收缩压(SBP)、舒张压(DBP)以及高血压患病率(定义为SBP≥140 mmHg、DBP≥90 mmHg或正在接受高血压治疗)。接受高血压治疗的受试者(N = 299)被排除在SBP和DBP分析之外,但纳入高血压患病率分析。
亚临床甲状腺功能减退受试者(N = 105)与甲状腺功能正常受试者(N = 1859)之间的平均SBP、DBP和高血压患病率无显著差异,血清促甲状腺激素(TSH)浓度处于参考范围上限(2.0 - 4.0 mU/l;N = 418)的受试者与TSH浓度处于参考范围下限(0.4 - 2.0 mU/l;N = 1441)的受试者之间也无显著差异。亚临床甲状腺功能亢进受试者的高血压患病率高于甲状腺功能正常受试者(年龄、年龄平方和性别校正后的患病率比值比为2.8,95%置信区间为1.3 - 6.0),但这是基于少量亚临床甲状腺功能亢进受试者(N = 35)得出的。
亚临床甲状腺功能减退与高血压无关。亚临床甲状腺功能亢进与高血压之间观察到的关联需要在更大样本中得到证实。